A Combination of Pathway-Targeted Inhibitor with DNA-Repair Inhibitor: Preclinical Efficacy of Zactima and Olaparib in Triple Negative Subset of Breast Cancer.

被引：0
|
作者：
Dey, N. [1 ]
Wu, H. [1 ]
Sun, Y. [1 ]
De, P. [1 ]
Leyland-Jones, B. [1 ]
机构：
[1] Emory Univ, Atlanta, GA 30322 USA
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/0008-5472.SABCS11-P3-18-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-18-02
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Preclinical efficacy of the combination of olaparib plus carboplatin with vandetanib in triple-negative breast cancer.
    Dey, Nandini
    Wu, Hui
    Sun, Yuliang
    De, Pradip
    Leyland-Jones, Brian
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] Preclinical activity of INK128, a TORC1/2 inhibitor, in triple negative breast cancer: A combination of PARP inhibitor with PI3K-mTOR pathway-targeted inhibitor
    Leyland-Jones, Brian
    Wu, Hui
    Sun, Yuliang
    Rommel, Christian
    Yi, Liu
    De, Pradip
    Dey, Nandini
    CANCER RESEARCH, 2012, 72
  • [3] Radiotherapy improves efficacy of the PARP inhibitor Niraparib in a preclinical model of triple negative breast cancer
    Binder, P.
    Katopodi, T.
    Hanson, L.
    Bell, C.
    Flanagan, E.
    Farrington, P.
    Moore, N.
    Wright, E.
    Bunday, T.
    Brown, S.
    Cantrell, A.
    Greenall, J.
    Sharman, S.
    Woolley, J.
    Mooney, L.
    Kendrew, J.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S125 - S125
  • [4] Preclinical Efficacy of the Combination of Met and Src Family Kinase Inhibitors in Triple-Negative Breast Cancer.
    Gartner, E. M.
    Kim, E. M. H.
    Choi, L.
    Boerner, J.
    CANCER RESEARCH, 2011, 71
  • [5] Combining electrochemotherapy with PARP inhibitor olaparib in triple negative breast cancer in vitro and in vivo
    Bosnjak, M.
    Jesenko, T.
    Markelc, B.
    Janzic, L.
    Cemazar, M.
    Sersa, G.
    FEBS OPEN BIO, 2021, 11 : 430 - 431
  • [6] Selinexor, a selective inhibitor of nuclear export, demonstrates efficacy in preclinical models of triple negative breast cancer
    Arango, N. Paez
    Evans, K. W.
    Zhao, M.
    Yuca, E.
    Scott, S. M.
    Janku, F.
    Ueno, N. T.
    Tripathy, D.
    Kim, C.
    Naing, A.
    Funda, M-B
    CANCER RESEARCH, 2017, 77
  • [7] Phase I trial of olaparib (PARP inhibitor) and vistusertib (mTORC1/2 inhibitor) in recurrent endometrial, ovarian and triple negative breast cancer.
    Westin, Shannon Neville
    Litton, Jennifer Keating
    Williams, Rochelle A.
    Shepherd, Christopher J.
    Brugger, Wolfram
    Pease, Elizabeth J.
    Soliman, Pamela T.
    Frumovitz, Michael M.
    Levenback, Charles F.
    Sood, Anil
    Meyer, Larissa
    Moulder, Stacy L.
    Valero, Vicente
    Saleem, Sadia
    Rodriguez, Anna Marie
    Cyriac, Annies
    Engerman, Laverne
    Samuel, Christine
    Mills, Gordon B.
    Coleman, Robert L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Preclinical efficacy of dasatinib in combination with PARP inhibitor plus standard cytotoxic agent in triple-negative breast cancer xenograft model
    Sun, Y.
    Lin, X.
    Carlson, Jh
    De, P.
    Dey, N.
    Williams, C.
    Leyland-Jones, B.
    CANCER RESEARCH, 2017, 77
  • [9] Pre-clinical combination of a PARP inhibitor, talazoparib, and carboplatin in triple-negative breast cancer.
    Cotte, Alexia
    Beniey, Michele
    Haque, Takrima
    Bechir, Nelly
    Hubert, Audrey
    Diallo, Korotoum W.
    Tran-Thanh, Danh
    Hassan, Saima N.
    CANCER RESEARCH, 2021, 81 (13)
  • [10] SYNERGISTIC INTERACTION BETWEEM OLAPARIB, A PARP INHIBITOR, AND CYTOTOXIC AGENT IN TRIPLE NEGATIVE BREAST CANCER
    Hashimoto, J.
    Kitamura, Y.
    Takashima, Y.
    Kodera, Y.
    Shimma, S.
    Hamada, A.
    Fujiwara, Y.
    Koizumi, F.
    Tamura, K.
    ANNALS OF ONCOLOGY, 2013, 24
12345